Adhera Therapeutics, Inc. (OTCQB: ATRX), a clinical stage biopharmaceutical company, announces that the Company has entered a Heads of Terms (also known as a Letter of Intent) agreement with Bio Innovation Group to acquire Paclitaxel Gallium Transferrin, a novel protein complex for targeted treatment of advanced cancers.
PGT is designed to deliver paclitaxel to cancer cells over-expressing Transferrin Receptor 1, also known as CD71 or TFR1. Paclitaxel is a commercially successful drug approved by the U.S. Food and Drug Administration in two variations, solvent-based paclitaxel (sb-paclitaxel, brand name Taxol®) and protein-based paclitaxel (nab-paclitaxel, brand name ABRAXANE®). Sb-paclitaxel is approved for breast, ovarian, and lung cancer and Kaposi’s Sarcoma, while nab-paclitaxel is approved for breast, pancreatic, and non-small cell lung cancer. Each are often used off-label for a variety of hard-to-treat solid and liquid tumors.
Read more here